title: Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
authors.affiliation: Rutgers Cancer Institute of New Jersey; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: mark.stein@rutgers.edu.
authors.forename: Mark N
authors.initials: MN
authors.lastname: Stein
authors.affiliation: Rutgers Cancer Institute of New Jersey; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
authors.forename: Kim M
authors.initials: KM
authors.lastname: Hirshfield
authors.affiliation: Rutgers Cancer Institute of New Jersey; Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhong
authors.affiliation: Rutgers Cancer Institute of New Jersey; Section of Urologic Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
authors.forename: Eric A
authors.initials: EA
authors.lastname: Singer
authors.affiliation: Foundation Medicine, Cambridge, Massachusetts, USA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Rutgers Cancer Institute of New Jersey; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
authors.forename: Shridar
authors.initials: S
authors.lastname: Ganesan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000077547:Crizotinib; D018450:Disease Progression; D057915:Drug Substitution; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: C551661:ARQ 197; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011760:Pyrrolidinones; D011804:Quinolines; D000077547:Crizotinib; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met